Get the Stockscreener App
22.76
0.98%
0.22
After Hours:
22.76
Surrozen Inc stock is traded at $22.76, with a volume of 150.24K.
It is up +0.98% in the last 24 hours and up +3.45% over the past month.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
See More
Previous Close:
$22.54
Open:
$22.34
24h Volume:
150.24K
Relative Volume:
0.74
Market Cap:
$267.51M
Revenue:
$7.49M
Net Income/Loss:
$-360.50M
P/E Ratio:
-0.5508
EPS:
-41.3227
Net Cash Flow:
$-33.68M
1W Performance:
+1.52%
1M Performance:
+3.45%
6M Performance:
-20.25%
1Y Performance:
+82.81%
1-Day Range:
$21.54
$22.90
1-Week Range:
$21.45
$23.00
52-Week Range:
$11.25
$35.00
Surrozen Inc Stock (SRZN) Company Profile
Name
Surrozen Inc
Sector
Industry
Phone
650-475-2820
Address
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Compare SRZN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRZN
Surrozen Inc
|
22.76 | 276.21M | 7.49M | -360.50M | -33.68M | -41.32 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | TD Cowen | Buy |
| Feb-19-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-30-25 | Initiated | H.C. Wainwright | Buy |
| Jan-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Sep-15-21 | Initiated | Guggenheim | Buy |
| Sep-07-21 | Initiated | Stifel | Buy |
View All
Surrozen Inc Stock (SRZN) Latest News
Surrozen Inc. Warrant (SRZNW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Discipline and Rules-Based Execution in SRZN Response - news.stocktradersdaily.com
Surrozen to Present at Upcoming Healthcare Investor Conferences - Yahoo Finance
Surrozen Inc. Warrant (SRZNW) Key Financial Ratios – Valuation, Profitability & More - Value Research
William Blair Upgrades Surrozen (NASDAQ:SRZN) to "Strong-Buy" - MarketBeat
William Blair Initiates Surrozen at Outperform - marketscreener.com
William Blair initiates Surrozen stock with Outperform rating By Investing.com - Investing.com Canada
William Blair initiates Surrozen stock with Outperform rating - Investing.com
Surrozen (SRZN) Q2 2026 Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
LifeSci Capital Maintains Surrozen(SRZN.US) With Buy Rating, Maintains Target Price $46 - Moomoo
SRZN Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers Strong Beat as Stage Remains Pre-Revenue - vinanet.vn
Braidwell group reports 3.9% Surrozen (SRZN) holding in amended 13G filing - Stock Titan
Surrozen (SRZN): Boxer Capital group discloses 8.9% ownership stake in 13G/A - Stock Titan
Liquidity Mapping Around (SRZN) Price Events - Stock Traders Daily
StemPoint Capital reports 5.0% Surrozen (SRZN) stake via shares and warrants - Stock Titan
Analysts Just Made A Massive Upgrade To Their Surrozen, Inc. (NASDAQ:SRZN) Forecasts - simplywall.st
What is HC Wainwright's Estimate for Surrozen Q3 Earnings? - MarketBeat
Surrozen (SRZN): 5AM Ventures group reports 7.8% beneficial ownership stake - Stock Titan
Surrozen: Buy Rating Reiterated as Clinical Roadmap Clarifies and IP Strengthens; Price Target Maintained at $44 - TipRanks
HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN) - MarketBeat
H.C. Wainwright reiterates Surrozen stock rating at buy, $44 target - Investing.com India
Surrozen Inc (SRZN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SRZN Q1 2026 Earnings: Wider-Than-Expected Loss Despite 18.39% Share RallyRevenue Guidance Range - vinanet.vn
Surrozen (SRZN) warrants expiring 2026 removed from Nasdaq listing - Stock Titan
Surrozen, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Surrozen earnings beat by $0.88, revenue topped estimates - Investing.com Canada
Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS - MarketBeat
Surrozen, Inc. 2Q 2026: Revenue $5M, Net income $50.18M, EPS $(0.41) — 10-Q Summary - TradingView
Surrozen (NASDAQ: SRZN) swings to $50.2M profit on Boehringer milestone revenue - Stock Titan
BRIEF-Surrozen Q2 Operating Income USD -10.37 Million - TradingView
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Surrozen, Inc. expected to post a loss of $1.29 a shareEarnings Preview - TradingView
Why (SRZN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN - MarketBeat
Surrozen Inc. Warrant (SRZNW) Holds at $0.01 as Trading Remains FlatElliott Wave Entry - dars.gov.et
Price to earnings forward of Surrozen, Inc. – BOATS:SRZNW - TradingView
SRZN Q1 2026 Earnings: Significant EPS Miss but Stock Rises Amid SpeculationBook Value Growth - vinanet.vn
SRZN Q1 2026 Earnings: Deep Loss Surprises as Pre-Revenue Biotech Advances PipelineOperating Income Trends - vinanet.vn
Surrozen, Inc. Revenue Breakdown – NASDAQ:SRZN - TradingView
Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock - MarketBeat
Surrozen Inc (SRZN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Surrozen Inc (SRZN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Surrozen Inc (SRZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Surrozen Inc (SRZN) Cash Flow - TradingKey
SRZN|Surrozen Inc|Price:25.620|Chg%:+3.980 - TradingKey
SRZN|Surrozen Inc|Price:19.660|Chg%:-0.070 - TradingKey
Surrozen Inc (SRZN) Income Statement - TradingKey
Form 4 Surrozen Inc For: 24 July By Investing.com - Investing.com Nigeria
TCG Crossover GP II sells $6.9 million in Surrozen shares By Investing.com - Investing.com Canada
TCG Crossover GP II sells $6.9 million in Surrozen shares - Investing.com
Surrozen (SRZN): TCG Crossover funds, Chen Yu disclose 9.9% stake - Stock Titan
Surrozen Inc Stock (SRZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Surrozen Inc Stock (SRZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Li Yang | Exec. Vice President, Research |
May 04 '26 |
Sale |
33.33 |
1,584 |
52,799 |
17,216 |
| Williams Charles O | Chief Operating Officer |
May 04 '26 |
Sale |
33.33 |
2,036 |
67,866 |
16,571 |
| Parker Craig C | Chief Executive Officer |
May 04 '26 |
Sale |
33.33 |
4,524 |
150,798 |
16,553 |
| TCG Crossover GP II, LLC | 10% Owner |
Mar 24 '26 |
Buy |
24.69 |
106,658 |
2,633,717 |
736,554 |
| TCG Crossover GP II, LLC | 10% Owner |
Mar 23 '26 |
Buy |
24.90 |
15,223 |
379,051 |
683,225 |
| TCG Crossover GP II, LLC | 10% Owner |
Mar 13 '26 |
Buy |
24.88 |
35,433 |
881,463 |
675,018 |
| TCG Crossover GP II, LLC | 10% Owner |
Mar 12 '26 |
Buy |
24.99 |
12,374 |
309,166 |
657,301 |
| TCG Crossover GP II, LLC | 10% Owner |
Mar 16 '26 |
Buy |
24.99 |
1,190 |
29,733 |
675,613 |
| TCG Crossover GP II, LLC | 10% Owner |
Feb 11 '26 |
Buy |
23.57 |
17,763 |
418,763 |
650,567 |
| TCG Crossover GP II, LLC | 10% Owner |
Feb 12 '26 |
Buy |
23.86 |
1,093 |
26,082 |
651,114 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):